Overview

This trial is active, not recruiting.

Condition hiv
Treatments measurement and communication of hiv risk, standard hiv testing and counseling
Sponsor Rakai Health Sciences Program
Collaborator Bill and Melinda Gates Foundation
Start date November 2014
End date June 2016
Trial size 968 participants
Trial identifier NCT02775357, OPP1118591

Summary

The study is aimed at testing whether use of a new index to measure risk for HIV in the context of HIV testing and counseling will increase demand for safe male circumcision (SMC) services among HIV-negative non-muslim men in Rakai. We will also study whether use of the index leads to positive sexual behavioral modifications among men. The study will also measure acceptability of the index among men.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking single blind (outcomes assessor)
Primary purpose prevention
Arm
(Experimental)
In addition to standard HIV testing and counseling,men randomized to this arm received Measurement and communication of HIV risk from the HIV counselors using an index developed and validated through the Rakai community cohort study. Their risk was communicated to them and subsequent HIV risk reduction counseling including male circumcision was given.
measurement and communication of hiv risk
Measurement and communication of HIV risk in the context of HIV testing and counseling to inform HIV risk reduction counseling
(Active Comparator)
Men randomized to this arm were given standard HIV testing and counseling following the current Uganda Ministry of Health guidelines. Following the counseling HIV risk reduction counseling including male circumcision was given.
standard hiv testing and counseling
Participants received HIV testing and counseling following standard Ministry of Health guidelines

Primary Outcomes

Measure
Circumcision status as reported on a questionnaire and confirmed by examination
time frame: 6 months

Secondary Outcomes

Measure
Condom use at last non-marital relationship as reported on a questionnaire
time frame: 6 months

Eligibility Criteria

Male participants from 15 years up to 49 years old.

Inclusion Criteria: - Uncircumcised, non-muslim, HIV-negative, sexually active in the previous 12 months Exclusion Criteria: - Refuses HIV testing, not willing to stay in Rakai for at least 6 months following enrollment or unwilling to be traced

Additional Information

Official title Using the Rakai HIV Risk Index to Measure and Communicate HIV Risk to Create Demand for Safe Male Circumcision: A Randomized Controlled Trial
Principal investigator Joseph Kagaayi, Ph.D
Description Three randomized trials, one of which was conducted in Rakai, Uganda, have shown that safe male circumcision (SMC) reduces HIV acquisition in men by approximately 60%. Recommendations from the World Health Organization (WHO) and the Joint United Nations Programme (UNAIDS) emphasize that SMC should be considered an efficacious intervention for HIV prevention in countries and regions with heterosexual epidemics, high HIV and low male circumcision prevalence. In Sub Saharan Africa, 14 countries including Uganda have been selected to scale up SMC, for these countries the target is to achieve 80% circumcision prevalence by 2015 and maintain it till 2025. The scale up would avert more than 20 percent of new infections among men and women. However SMC programs are faced with the challenge of low uptake of SMC by older sexually active men who might be at higher risk of HIV. The need to increase SMC coverage among men at high risk of HIV requires tools to measure individual HIV risk. Rakai Health Sciences Program has received funding to carry out an individual randomized, unblinded, two-arm 1:1 trial comprising a total of 968 men (484 men per study arm) from Rakai Community Cohort Study (RCCS) to assess whether HIV Counseling and Testing (HCT), enhanced with measurement and communication of HIV risk (eHCT), increases uptake of SMC and leads to behavior modification among HIV-negative sexually active men aged 15-49 years in Rakai District, Uganda. The study is using a risk nomogram developed from the Rakai Community Cohort Study data to measure individual HIV risk in the intervention group and standard HCT in the control arm. All men enrolled will be followed at six months to ascertain circumcision status and collect brief information on sexual behaviors such as number of sex partners, use of alcohol with sex, detailed data on their sexual partners etc.The study will also measure acceptability of the index among men.
Trial information was received from ClinicalTrials.gov and was last updated in May 2016.
Information provided to ClinicalTrials.gov by Rakai Health Sciences Program.